Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Orexigen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.56 Insider Own0.10% Shs Outstand123.17M Perf Week9.20%
Market Cap774.74M Forward P/E- EPS next Y-0.31 Insider Trans206.62% Shs Float122.26M Perf Month11.92%
Income-59.60M PEG- EPS next Q0.23 Inst Own88.10% Short Float29.95% Perf Quarter31.87%
Sales33.40M P/S23.20 EPS this Y37.00% Inst Trans7.50% Short Ratio9.80 Perf Half Y3.28%
Book/sh0.14 P/B44.93 EPS next Y-181.80% ROA-37.60% Target Price11.33 Perf Year15.20%
Cash/sh0.96 P/C6.53 EPS next 5Y13.90% ROE-297.30% 52W Range3.11 - 7.82 Perf YTD11.72%
Dividend- P/FCF- EPS past 5Y21.90% ROI-63.30% 52W High-19.57% Beta2.46
Dividend %- Quick Ratio7.00 Sales past 5Y102.40% Gross Margin- 52W Low102.25% ATR0.34
Employees50 Current Ratio7.10 Sales Q/Q3500.60% Oper. Margin- RSI (14)65.31 Volatility5.24% 4.57%
OptionableYes Debt/Eq4.91 EPS Q/Q147.40% Profit Margin- Rel Volume1.10 Prev Close6.38
ShortableYes LT Debt/Eq4.91 EarningsNov 10 BMO Payout- Avg Volume3.74M Price6.29
Recom1.70 SMA207.67% SMA5027.24% SMA20014.19% Volume4,095,600 Change-1.41%
Jan-10-14Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Outperform $10
Sep-21-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $5
Feb-01-11Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-01-11Downgrade Canaccord Genuity Buy → Hold
Dec-03-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform
Jul-16-10Reiterated JMP Securities Mkt Outperform $16 → $13
Jul-16-10Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Feb-02-10Initiated Jefferies & Co Buy $12
Jun-24-09Initiated Rodman & Renshaw Mkt Outperform $14
Mar-13-09Reiterated Lazard Capital Mkts Buy $13 → $10
Apr-03-08Initiated Cowen & Co Outperform
Feb-06-08Initiated Lazard Capital Buy
Feb-04-08Reiterated Canaccord Adams Buy $29 → $32
Jan-03-08Initiated JP Morgan Overweight
Oct-03-07Upgrade JMP Securities Mkt Outperform → Strong Buy $26
Jun-07-07Initiated JP Morgan Overweight
Jun-06-07Initiated JMP Securities Mkt Outperform $26
Dec-18-14 01:44PM  Six Biotech and Technology Stocks With Strong Technical Set-Ups at TheStreet
Dec-17-14 07:42AM  Bio-Twitter Sentiment Favors European Orexigen Obesity Pill Approval Yahoo Finance Blogs +7.77%
Dec-12-14 11:58AM  Obesity Pill Upstart Orexigen Therapeutics Gaining on Rivals Yahoo Finance Blogs
Dec-08-14 03:31PM  These 4 Biotech Stocks Have Been On Fire Benzinga
Dec-05-14 05:50AM  Why Orexigen Therapeutics (OREX) Stock Might be a Great Pick Zacks
Dec-03-14 05:51AM  Earnings Estimates Moving Higher for Orexigen (OREX): Time to Buy? Zacks
Nov-26-14 08:30AM  Orexigen Therapeutics to Present at the Piper Jaffray Healthcare Conference PR Newswire
Nov-21-14 08:00AM  Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl extended release) PR Newswire
Nov-19-14 01:50PM  Is Orexigen Really Worth Over 50% More? at 24/7 Wall St.
Nov-18-14 01:04PM  OREXIGEN THERAPEUTICS, INC. Financials EDGAR Online Financials
Nov-17-14 11:33AM  2 Skyrocketing Biotech Stocks In A Stalling Market Benzinga
Nov-14-14 06:00AM  Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind at TheStreet
Nov-13-14 01:28PM  Nasdaq stocks posting largest percentage increases AP
12:10PM  What's Driving Orexigen Therapeutics Higher? Benzinga
Nov-12-14 07:09PM  10-Q for Orexigen Therapeutics, Inc. Company Spotlight +15.87%
04:42PM  A ho-hum day in the markets as stocks open weaker, but recover to close mixed... Yahoo Finance Blogs
01:02PM  Orexigen Therapeutics Continues To Rally at TheStreet
Nov-11-14 10:20AM  Orexigen Turns Around with Q3 Earnings Beat, Shares Soar Zacks
09:46AM  Today's Perilous Reversal Stock: Orexigen Therapeutics (OREX) at TheStreet
06:38AM  Orexigen (OREX) Worth Watching: Stock Soars 33.3% Zacks
Nov-10-14 02:53PM  Orexigen Therapeutics (OREX) Stock Continues to Rise as EU Reviews Contrave Drug at TheStreet +33.25%
11:02AM  Orexigen rises as weight loss drug review proceeds AP
10:33AM  Orexigen Therapeutics (OREX) Stock Soars Today on Big Third Quarter Earnings Beat at TheStreet
08:30AM  Orexigen Therapeutics Inc Earnings Call scheduled for 8:30 am ET today CCBN
07:18AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
07:07AM  Q3 2014 Orexigen Therapeutics Inc Earnings Release - Before Market Open CCBN
07:00AM  Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014 PR Newswire
Nov-06-14 04:30PM  Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference PR Newswire
Nov-04-14 04:15PM  Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast PR Newswire
Oct-31-14 08:30AM  Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in Boston PR Newswire
Oct-22-14 07:32AM  Orexigen (OREX) Shows Strength: Stock Gains 11.1% Zacks
Oct-20-14 08:00AM  Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults PR Newswire
Oct-16-14 01:25PM  Orexigen Up on $100M Milestone Payment from Takeda Zacks +5.28%
Oct-15-14 04:27PM  AbbVie and Bank of America are big market movers AP +15.03%
04:01PM  Shire PLC Takes A Dive As AbbVie Reconsiders Offer at TheStreet
08:30AM  Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial Launch PR Newswire
Sep-18-14 08:25AM  The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead Zacks
Sep-17-14 02:00PM  Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved Zacks
Sep-16-14 04:15PM  Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference PR Newswire
10:30AM  Insider Trading Alert - HTGC, OREX And TEP Traded By Insiders at TheStreet
Sep-15-14 06:00AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online -5.43%
05:51AM  Selling Obesity Drugs to Americans Shouldn't Be This Hard at BusinessWeek
Sep-12-14 04:10PM  Novo Nordisk's Saxenda Gets Positive Opinion for Obesity Zacks
01:20PM  Nasdaq stocks posting largest percentage decreases AP
11:00AM  [video] Orexigen's anti-obesity pill wins FDA Approval at CNBC
Sep-11-14 05:23PM  FDA panel backs Novo Nordisk injection for obesity AP -10.51%
05:15PM  [video] Orexigen drops in spite of FDA approval at CNBC
04:10PM  How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval? at TheStreet
04:00PM  U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Reuters
03:30PM  Orexigen's Obesity Drug Contrave Approved by the FDA Zacks
01:49PM  FDA approves weight-loss drug Contrave AP
01:23PM  Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised at TheStreet
01:11PM  [video] Orexigen's obesity pill at CNBC
12:50PM  [$$] FDA Approves Weight-Loss Drug at The Wall Street Journal
10:34AM  Long-awaited diet pill gets U.S. approval Reuters
08:30AM  Orexigen Therapeutics Call scheduled for 8:30 am ET today CCBN
07:40AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
07:00AM  Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management PR Newswire
Sep-10-14 09:16PM  New Drug to Treat Obesity Gains Approval by F.D.A. at New York Times
07:58PM  FDA Approves Contrave Weight Loss Drug From Orexigen And Takeda at Forbes
07:46PM  Orexigen Therapeutics to Host Conference Call and Webcast At 8:30 AM Eastern Time September 11, 2014 PR Newswire
07:00PM  Orexigen Wins U.S. FDA Approval for Weight-Loss Pill at Bloomberg
Sep-08-14 05:15PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
Sep-02-14 08:00AM  Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent PR Newswire
Aug-19-14 10:45AM  You've got obesity all wrong: Zafgen CEO at CNBC
Aug-08-14 05:13PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
08:20AM  Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount Zacks
Aug-07-14 08:00AM  Orexigen Therapeutics Inc Earnings Call scheduled for 8:00 am ET today CCBN
07:20AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
07:07AM  Q2 2014 Orexigen Therapeutics, Inc. Earnings Release - Before Market Open CCBN
07:00AM  Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014 PR Newswire
Jul-31-14 08:00AM  Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast PR Newswire
Jul-30-14 01:21PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
08:00AM  Orexigen Receives CHMP Day 180 List of Outstanding Issues PR Newswire
Jul-21-14 09:46AM  Perilous Reversal Watch: Orexigen Therapeutics (OREX) at TheStreet
Jul-19-14 04:14PM  The Implications of Obesity as a Disability in Europe at Motley Fool
Jul-18-14 10:09AM  Trade-Ideas: Orexigen Therapeutics (OREX) Is Today's "Dead Cat Bounce" Stock at TheStreet +5.56%
05:47AM  Call buyers returning to Orexigen optionMONSTER
Jul-15-14 06:50PM  Arena Pharmaceuticals Inc. Still Down After CEO's Sale at Motley Fool
Jul-11-14 01:01PM  Arena Stock Holds On Expected Dip In Sales - Bottom May Be In at Seeking Alpha
06:14AM  Bull throws weight behind Orexigen optionMONSTER
Jul-10-14 11:54AM  14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014 at TheStreet
Jul-03-14 04:11PM  3 Stocks Even Volatility-Loving Nasdaq Investors Hate at Motley Fool
04:06PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Subm EDGAR Online
Jul-01-14 06:09PM  The Next Orphan Drug Multibagger and Future Obesity Champion? at Motley Fool
Jun-27-14 05:30PM  Are Investors Wrong About Orexigen Therapeutics? at Motley Fool
05:01PM  3 Biotech Stocks with Catalysts Incoming: Spectrum, Orexigen, and Avanir at Motley Fool
Jun-25-14 05:30PM  Are Investors Wrong About VIVUS? at Motley Fool
Jun-24-14 06:20AM  How Bad Is This Delay for Orexigen Therapeutics, Inc? at Motley Fool
Jun-20-14 11:34AM  The Anti-Obesity Space Is Not As Simple As Some Think at Seeking Alpha
03:19AM  Now Available: Shares in Zafgen, the Best Obesity Drugmaker to Date at Motley Fool
Jun-19-14 03:12PM  Why Zafgen Inc. Shares Roared Higher at Motley Fool
07:24AM  The Zacks Analyst Blog Highlights: Idenix, Achillion Pharmaceuticals, Nektar, Orexigen, Celgene, Alexion and Biogen Zacks
Jun-18-14 09:33AM  Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar Zacks
Jun-17-14 07:41AM  Orexigen (OREX) in Focus: Stock Moves 7.5% Higher Zacks
Jun-16-14 04:19PM  What Will It Take For Arena Stock To Rise? at Seeking Alpha +7.52%
08:00AM  3 Stocks Crushed by the Market This Week at Motley Fool
Jun-15-14 11:20AM  This Week in Biotech: Actions Speak Louder Than Words at Motley Fool
Jun-13-14 05:32PM  Is It Time to Buy Orexigen? at Motley Fool
02:56PM  Vivus Suit Preserves Exclusivity Of Qsymia - For Now at Seeking Alpha
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Turner Heather DSVP, Gen. Counsel & SecretaryDec 02Option Exercise1.6622,64337,58722,643Dec 04 05:05 PM
Turner Heather DSVP, Gen. Counsel & SecretaryDec 02Sale6.0022,643135,8580Dec 04 05:05 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 25Option Exercise1.667,38212,2547,382Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 25Sale6.007,38244,2920Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 24Option Exercise1.6624,00639,85024,006Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 24Sale5.7724,006138,5870Nov 26 05:01 PM
BOCK LOUIS CDirectorNov 18Buy5.587003,905700Nov 20 09:16 AM
BOCK LOUIS CDirectorNov 18Buy5.586253,48727,677Nov 20 09:16 AM
BOCK LOUIS CDirectorNov 12Buy5.5727,052150,54427,052Nov 13 09:27 AM
Turner Heather DVP, Gen. Counsel & SecretarySep 22Option Exercise1.66300,000498,000300,000Sep 22 06:49 PM
Turner Heather DVP, Gen. Counsel & SecretarySep 22Sale4.47300,0001,339,5000Sep 22 06:49 PM
Hagan Joseph PSr. VP, Corporate DevelopmentSep 15Buy4.695,00023,45013,026Sep 15 03:11 PM
NARACHI MICHAELPresident and CEOSep 15Buy4.7850,000239,10058,026Sep 15 02:41 PM
DOVEY BRIAN HDirectorApr 22Option Exercise0.004,691,4704,6917,580,065Apr 23 05:15 PM